Supports investigator-initiated mid-phase clinical trials of natural products including botanicals, dietary supplements, and probiotics. Trials should determine optimal dosing or patient phenotypes for future efficacy studies. Requires strong preliminary data on bioavailability and target engagement. Excludes cancer treatment/prevention and efficacy/effectiveness trials. Applications must be hypothesis-driven and milestone-based, aligned with NCCIH research priorities.
Eligible applicants include a wide range of organizations such as academic institutions, nonprofits, small businesses, tribal governments, and various government entities. Non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible.
